Passage Bio to Present at Guggenheim Healthcare Talks: Genomic Medicines and Rare Disease Days
Passage Bio (NASDAQ: PASG), a clinical stage genetic medicines company, announced that CEO William Chou, M.D., will take part in a fireside chat at the Guggenheim Healthcare Talks: Genomic Medicines and Rare Disease Days on April 3, 2023, at 3:55 p.m. ET in New York. A live webcast of the chat will be available on the company's Investors & Media section. Passage Bio focuses on developing transformative therapies for central nervous system (CNS) disorders, including GM1 gangliosidosis and frontotemporal dementia, with strong collaborations enhancing their research capabilities.
- None.
- None.
PHILADELPHIA, March 27, 2023 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical stage genetic medicines company focused on developing transformative therapies for central nervous system (CNS) disorders, today announced that William Chou, M.D., chief executive officer, will participate in a fireside chat at the upcoming Guggenheim Healthcare Talks: Genomic Medicines and Rare Disease Days on Monday, April 3, 2023 at 3:55 p.m. ET in New York, NY.
A live webcast of the event will be available on the Investors & Media section of Passage Bio’s website at investors.passagebio.com. A replay of the presentation will be available for 30 days following the event.
About Passage Bio
Passage Bio (Nasdaq: PASG) is a clinical stage genetic medicines company on a mission to provide life-transforming therapies for patients with CNS diseases with limited or no approved treatment options. Our portfolio spans pediatric and adult CNS indications, and we are currently advancing clinical programs in GM1 gangliosidosis and frontotemporal dementia and our preclinical pipeline, including programs in amyotrophic lateral sclerosis and Huntington’s disease. Based in Philadelphia, PA, our company has established a strategic collaboration and licensing agreement with the renowned University of Pennsylvania’s Gene Therapy Program to conduct our discovery and IND-enabling preclinical work. Through this collaboration, we have enhanced access to a broad portfolio of gene therapy candidates and future gene therapy innovations that we then pair with our deep clinical, regulatory, manufacturing and commercial expertise to rapidly advance our robust pipeline of optimized gene therapies. As we work with speed and tenacity, we are always mindful of patients who may be able to benefit from our therapies. More information is available at www.passagebio.com.
For further information, please contact:
Passage Bio Investors:
Stuart Henderson
Passage Bio
267.866.0114
shenderson@passagebio.com
Passage Bio Media:
Mike Beyer
Sam Brown Inc. Healthcare Communications
312.961.2502
MikeBeyer@sambrown.com
FAQ
What is the date and time of the Passage Bio fireside chat?
Where can I watch the Passage Bio fireside chat?
Who is participating in the Passage Bio fireside chat?
What does Passage Bio specialize in?
What are the key diseases being targeted by Passage Bio?
